Gut microbiota in multiple sclerosis: immunological mechanisms and therapeutic implications
Abstract
Multiple sclerosis is a chronic autoimmune disorder characterised by inflammation, demyelination, and progressive neurodegeneration within the central nervous system. In recent years, increasing attention has been directed towards the potential role of the gut microbiota in the pathogenesis of multiple sclerosis. Intestinal microorganisms interact with the immune system and may influence neuroinflammatory processes through the gut–brain axis. Growing evidence suggests that disturbances in gut microbial composition may contribute to the immune dysregulation observed in patients with multiple sclerosis. The aim of this narrative review is to summarise current knowledge regarding alterations in gut microbiota composition in individuals with multiple sclerosis, as well as to discuss the immunological mechanisms linking intestinal microorganisms with disease development. A comprehensive literature search was performed using the PubMed, Scopus, and Web of Science databases. Studies addressing gut microbiota, immune mechanisms, and microbiota-targeted therapeutic strategies in multiple sclerosis were analysed and synthesised. Available evidence indicates that patients with multiple sclerosis often present alterations in gut microbial composition, including reduced abundance of beneficial commensal bacteria and increased representation of pro-inflammatory taxa. These changes may influence immune responses through mechanisms involving T-cell differentiation, cytokine signalling, and microbial metabolite production. Experimental and clinical studies also suggest that microbiota-targeted interventions, such as probiotic supplementation or modulation of microbial metabolites, including short-chain fatty acids, may affect inflammatory pathways involved in multiple sclerosis. Although current clinical evidence remains limited, a growing body of research indicates that modulation of the gut microbiota may represent a promising complementary strategy in the management of multiple sclerosis.